A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat
Study sponsor: SIGA Technologies
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2016-08-24Actual
Enrollment · participants449Actual
Source updated2026-09-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.